• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Navamedic

Less than 1K followers

NAVA

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Overview
Investor consensus

Navamedic is a Nordic pharmaceutical company that supplies pharmaceuticals, OTC, medical nutrition products for rare diagnoses and medical devices to hospitals and pharmacies in areas such as obesity, women's health, urology, gastrointestinal and pain. Navamedic operates in the Nordic countries, the Baltics and Benelux but is also represented in the UK and Greece. The company was established in 1999 and is headquartered in Oslo.

Read more
Market cap
-
Turnover
-
Revenue
565.36M
EBIT %
2.19 %
P/E
-
Dividend yield-%
-
Financial calendar
14.8
2026

Interim report Q2'26

29.10
2026

Interim report Q3'26

All
Press releases
3rd party
ShowingAll content types

Regulatory press release6/16/2026, 5:57 AM

Navamedic ASA: Change in leadership

Navamedic
Regulatory press release5/21/2026, 1:27 PM

NAVA: Navamedic launches Virono®- the first single-dose over-the-counter cold sore tablet

Navamedic
Press release5/21/2026, 1:27 PM

Navamedic ASA: Navamedic launches Virono®- the first single-dose over-the-counter cold sore tablet

Navamedic

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release5/20/2026, 10:45 AM

NAVA: Major shareholder disclosure in Navamedic ASA

Navamedic
Regulatory press release5/18/2026, 2:00 PM

Navamedic ASA: Mandatory notification of trade

Navamedic
Regulatory press release4/23/2026, 2:07 PM

Navamedic ASA: Minutes of Annual General Meeting

Navamedic
Regulatory press release4/23/2026, 2:06 PM

Navamedic ASA: Minutes of Annual General Meeting

Navamedic
Regulatory press release4/23/2026, 5:00 AM

Navamedic ASA: Steady performance and continued product launch in Q1 2026

Navamedic
Regulatory press release4/23/2026, 5:00 AM

Navamedic ASA: Steady performance and continued product launch in Q1 2026

Navamedic
Regulatory press release4/20/2026, 6:32 AM

Navamedic ASA: Invitation to presentation of first quarter 2026 results

Navamedic
Regulatory press release4/15/2026, 3:21 PM

Navamedic ASA: Recommendation of the nomination committee for the Annual General Meeting on 23 April 2026

Navamedic
Regulatory press release3/31/2026, 10:00 AM

Navamedic ASA: Notice of Annual General Meeting

Navamedic
Regulatory press release3/25/2026, 12:11 PM

NAVA: Annual Report 2025

Navamedic
Regulatory press release2/27/2026, 12:05 PM

Navamedic ASA: Mandatory notification of trade

Navamedic
Regulatory press release2/27/2026, 12:04 PM

Navamedic ASA: Mandatory notification of trade

Navamedic
Regulatory press release2/12/2026, 6:00 AM

Navamedic ASA: Strong growth and important product launch in Q4 2025

Navamedic
Regulatory press release2/12/2026, 6:00 AM

Navamedic ASA: Strong growth and important product launch in Q4 2025

Navamedic
Regulatory press release2/9/2026, 8:19 AM

Navamedic ASA: Invitation to presentation of fourth quarter 2025 results

Navamedic
Regulatory press release1/19/2026, 1:01 PM

NAVA: Financial calendar

Navamedic
Regulatory press release1/7/2026, 11:35 AM

Navamedic ASA: Minutes of Extraordinary General Meeting

Navamedic